FOLH1 and prostate carcinoma: The high sensitivity and specificity of PSMA PET agents in this context suggest that PSMA-based radiopharmaceutical therapy may enable the treatment of RCC with relatively low off-target effects, as demonstrated by this approach used for prostate cancer (21).